cURL Error: Failed to connect to 217.15.170.3 port 80 after 1030 ms: Couldn't connect to server Monitoring of BMY situation on June 12, 2025
Stocks Prognosis
cURL Error: Failed to connect to 217.15.170.3 port 80 after 1074 ms: Couldn't connect to server
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site

BMY: Bristol-Myers Squibb Co. Reports Positive Phase 3 Trial Results For Sotyktu

Published on June 12, 2025
Investors are taking notice of Bristol-Myers Squibb Company, as they have recently announced positive phase 3 trial results for their drug Sotyktu. This news has caused BMY shares to rise by 3.07% on June 10, capturing the attention of many in the market. With this promising development, many are curious to see how this will impact the future of the company and its stock. For a professional forecast on the movement of BMY shares, experts recommend consulting Stocks Prognosis.
Go to BMY Page

Investor opinions & comments

To leave a comment, you need to Login or Register.

There are no comments yet. Be the first to leave one!

Other Data for BMY

Bristol-Myers Squibb: A Strong Value Stock with Promising Future

December 7, 2025

BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.1% Profit Achieved

July 31, 2025

BRISTOL-MYERS SQUIBB COMPANY Stock Hits Forecast Price Target with 10.86% Profit

July 31, 2025

Bristol Myers Squibb NYSE:BMY Set to Revolutionize Cancer Treatment with Breakthrough Drug

June 23, 2025

QuantWave Successfully Achieves Price Target Forecast for Bristol-Myers Squibb Company with 14.06% Profit

May 14, 2025

BRISTOL-MYERS SQUIBB COMPANY Hits QuantWave Price Target with 13.0% Profit Margin

May 14, 2025

Related Data

Bristol Myers Squibb: Promising Results from Phase 3 Psoriatic Arthritis Trials

December 29, 2024

Bristol-Myers Squibb Makes Significant Progress in Psoriatic Arthritis Treatment

December 29, 2024

Positive Results from Psoriatic Arthritis Trials Boost Bristol-Myers Squibb Stock

December 26, 2024

New Drug Approval Boosts BMY Stocks: Analysts Recommend Buying Bristol-Myers Squibb Shares

January 13, 2025

Positive Development for Bristol-Myers Squibb Company's Breyanzi NHL Treatment

March 19, 2025